Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

Abstract : Anti-CD20-containing chemotherapy regimens have become the standard of care for patients with follicular lymphoma needing cytotoxic therapy. Four randomized trials demonstrated a clinical benefit for patients treated with rituximab. However, no long-term follow up (i.e. > 5 years) of these trials is yet available. Between May 2000 and May 2002, 358 newly diagnosed patients with high tumor burden follicular lymphoma were randomized to receive cyclophosphamide, adriamycin, etoposide and prednisolone plus interferon-α2a or a similar chemotherapy-based regimen plus rituximab, and outcome was up-dated. With a median follow up of 8.3 years, addition of rituximab remained significantly associated with prolonged event-free survival (primary end point) (P=0.0004) with a trend towards a benefit for overall survival (P=0.076). The Follicular Lymphoma International Prognostic Index score was strongly associated with outcome for both event-free and overall survival in univariate analysis and its prognostic value remained highly significant after adjusting for other significant covariates in multivariate models (P<0.0001 and P=0.001, respectively). Considering long-term toxicity, the addition of rituximab in the first-line setting was confirmed as safe with regards to development of secondary malignancies. Long-term follow up of patients with follicular lymphoma treated in the FL2000 study confirms the sustained clinical benefit of rituximab without long-term toxicity.
Type de document :
Article dans une revue
Haematologica, Ferrata Storti Foundation, 2013, 98 (7), pp.1107-14. 〈10.3324/haematol.2012.082412〉
Liste complète des métadonnées

Littérature citée [27 références]  Voir  Masquer  Télécharger

https://hal-univ-rennes1.archives-ouvertes.fr/hal-00933219
Contributeur : Morgane Le Corre <>
Soumis le : mercredi 11 octobre 2017 - 10:29:01
Dernière modification le : jeudi 12 octobre 2017 - 10:32:14

Fichier

1107.full.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Citation

Emmanuel Bachy, Roch Houot, Franck Morschhauser, Anne Sonet, Pauline Brice, et al.. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.. Haematologica, Ferrata Storti Foundation, 2013, 98 (7), pp.1107-14. 〈10.3324/haematol.2012.082412〉. 〈hal-00933219〉

Partager

Métriques

Consultations de
la notice

341

Téléchargements du document

6